Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia (Q42596157)

3 November 2017

title

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia (English)

1 reference

3 November 2017

Patrick C Walsh

1 reference

3 November 2017

Franklin C Lowe

1 reference

3 November 2017

John D McConnell

1 reference

3 November 2017

Perry B Hudson

1 reference

3 November 2017

Nicholas A Romas

1 reference

3 November 2017

Rex Boake

1 reference

3 November 2017

Michael Lieber

1 reference

3 November 2017

Mostafa Elhilali

1 reference

3 November 2017

Jack Geller

1 reference

3 November 2017

Juliane Imperto-McGinely

1 reference

3 November 2017

Gerald L Andriole

1 reference

3 November 2017

Reginald C Bruskewitz

1 reference

3 November 2017

Georg Bartsch

1 reference

3 November 2017

John N Nacey

1 reference

3 November 2017

Sukrut Shah

1 reference

3 November 2017

Frances Pappas

1 reference

3 November 2017

Amy Ko

1 reference

3 November 2017

Thomas Cook

1 reference

3 November 2017

Elizabeth Stoner

1 reference

3 November 2017

Joanne Waldstreicher

1 reference

3 November 2017

Finasteride Study Group

1 reference

3 November 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

3 November 2017

1 reference

3 November 2017

1 reference

3 November 2017

1 reference

3 November 2017

page(s)

791-796

1 reference

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Androgen Metabolism in Men Receiving Finasteride before Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902548-7

7 January 2021

10.1016/S0090-4295(02)02548-7

Identifiers

DOI

1 reference

release_vufqm4y7prh2vf2iartoxy37ku

3 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vufqm4y7prh2vf2iartoxy37ku

24 November 2022

mapped directly with Wikidata item

1 reference